Most Popular
-
1
Ador CEO denies allegations, accuses Hybe of mistreating NewJeans
-
2
Korea’s homegrown nanosatellite successfully launches into space
-
3
[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
4
Nicaragua shuts down Seoul embassy
-
5
Medical reform committee kicks off despite boycott from doctors
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
6
Hybe's multilabel system tested amid conflict with Ador
-
7
SNU profs to suspend treatment for one day
-
8
Rocket engine expert, ex-NASA exec to lead Korea's new space agency
-
9
SK hynix pledges W20tr to ramp up DRAM production at home
-
10
10-man S. Korea lose to Indonesia to miss out on Paris Olympic football qualification
[DISCLOSURE] CMG Pharmaceutical (058820) said on Oct. 27 that its third-quarter operating profit came in positive at 591 million won (US$519,560) on-year.
Sales increased 17.2 percent to 8.3 billion won and net profit came in positive at 555 million won.
By Jung Min-kyung (mkj1105@heraldcorp.com)
Sales increased 17.2 percent to 8.3 billion won and net profit came in positive at 555 million won.
By Jung Min-kyung (mkj1105@heraldcorp.com)
